Literature DB >> 11987791

Construction of first-generation adenoviral vectors.

Philip Ng1, Frank L Graham.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 11987791     DOI： 10.1385/1-59259-141-8:389

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN： 1543-1894


× No keyword cloud information.
  34 in total

1.  TRIF, and TRIF-interacting TLRs differentially modulate several adenovirus vector-induced immune responses.

Authors:  D M Appledorn; S Patial; S Godbehere; N Parameswaran; A Amalfitano
Journal:  J Innate Immun       Date:  2009-03-04       Impact factor: 7.349

2.  Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo.

Authors:  Sergey S Seregin; Yasser A Aldhamen; Daniel M Appledorn; Zachary C Hartman; Nathaniel J Schuldt; Jeannine Scott; Sarah Godbehere; Haixiang Jiang; Michael M Frank; Andrea Amalfitano
Journal:  Blood       Date:  2010-05-28       Impact factor: 22.113

3.  Sublingual administration of an adenovirus serotype 5 (Ad5)-based vaccine confirms Toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against HIV antigens despite preexisting Ad5 immunity.

Authors:  Daniel M Appledorn; Yasser A Aldhamen; Sarah Godbehere; Sergey S Seregin; Andrea Amalfitano
Journal:  Clin Vaccine Immunol       Date:  2010-11-17

4.  The contribution of transactivation subdomains 1 and 2 to p53-induced gene expression is heterogeneous but not subdomain-specific.

Authors:  Jennifer M Smith; Lawton J Stubbert; Jeffrey D Hamill; Bruce C McKay
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

5.  Manipulation of EAT-2 expression promotes induction of multiple beneficial regulatory and effector functions of the human innate immune system as a novel immunomodulatory strategy.

Authors:  Yasser A Aldhamen; Sergey S Seregin; Charles F Aylsworth; Sarah Godbehere; Andrea Amalfitano
Journal:  Int Immunol       Date:  2013-12-27       Impact factor: 4.823

6.  Large-scale production of high-quality helper-dependent adenoviral vectors using adherent cells in cell factories.

Authors:  Masataka Suzuki; Racel Cela; Christian Clarke; Terry K Bertin; Susana Mouriño; Brendan Lee
Journal:  Hum Gene Ther       Date:  2010-01       Impact factor: 5.695

7.  Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy.

Authors:  Sergey S Seregin; Daniel M Appledorn; Aaron J McBride; Nathaniel J Schuldt; Yasser A Aldhamen; Tyler Voss; Junping Wei; Matthew Bujold; William Nance; Sarah Godbehere; Andrea Amalfitano
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

8.  Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms.

Authors:  Neha Kamran; Marianela Candolfi; Gregory J Baker; Mariela Moreno Ayala; Marta Dzaman; Pedro R Lowenstein; Maria G Castro
Journal:  Methods Mol Biol       Date:  2016

9.  Convergence of Notch and beta-catenin signaling induces arterial fate in vascular progenitors.

Authors:  Kohei Yamamizu; Taichi Matsunaga; Hideki Uosaki; Hiroyuki Fukushima; Shiori Katayama; Mina Hiraoka-Kanie; Kohnosuke Mitani; Jun K Yamashita
Journal:  J Cell Biol       Date:  2010-04-19       Impact factor: 10.539

10.  A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target.

Authors:  Daniel M Appledorn; Yasser A Aldhamen; William Depas; Sergey S Seregin; Chyong-Jy J Liu; Nathan Schuldt; Darin Quach; Dionisia Quiroga; Sarah Godbehere; Igor Zlatkin; Sungjin Kim; J Justin McCormick; Andrea Amalfitano
Journal:  PLoS One       Date:  2010-03-08       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.